Browse News
Filter News
Found 9 articles
-
Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis
2/23/2023
Genascence Corporation announced it has been awarded $11.6 million over four years from the California Institute for Regenerative Medicine.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
As the American Society of Gene & Cell Therapy's 25th Annual Meeting wraps up, a host of life science companies touted their research and products. BioSpace looks at some of them.
-
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
-
Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting
5/17/2022
Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced that additional safety data from the Phase 1 clinical trial of GNSC-001.
-
Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board
5/10/2022
Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, announced it has completed the first closing in a Series A financing led by Pacira BioSciences, Inc., totaling $10.5 million.
-
BioSpace takes a look at data released this week from some of the numerous ongoing clinical studies to advance potential therapies and treatment for disease. Here are some of them.
-
Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis
5/5/2021
Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, announced that dosing across all three cohorts has been completed in the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis.